Free Trial

Cara Therapeutics (CARA) Competitors

$0.35
-0.01 (-2.76%)
(As of 07/12/2024 ET)

CARA vs. HILS, ELDN, OVID, ANEB, RMTI, VHAQ, VACC, BRNS, CELU, and RLYB

Should you be buying Cara Therapeutics stock or one of its competitors? The main competitors of Cara Therapeutics include Hillstream BioPharma (HILS), Eledon Pharmaceuticals (ELDN), Ovid Therapeutics (OVID), Anebulo Pharmaceuticals (ANEB), Rockwell Medical (RMTI), Viveon Health Acquisition (VHAQ), Vaccitech (VACC), Barinthus Biotherapeutics (BRNS), Celularity (CELU), and Rallybio (RLYB). These companies are all part of the "pharmaceutical preparations" industry.

Cara Therapeutics vs.

Cara Therapeutics (NASDAQ:CARA) and Hillstream BioPharma (NASDAQ:HILS) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, community ranking, valuation, risk, profitability, media sentiment, analyst recommendations, earnings and institutional ownership.

Hillstream BioPharma has a net margin of 0.00% compared to Cara Therapeutics' net margin of -723.49%. Cara Therapeutics' return on equity of -174.15% beat Hillstream BioPharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Cara Therapeutics-723.49% -174.15% -105.26%
Hillstream BioPharma N/A -188.44%-149.61%

In the previous week, Cara Therapeutics had 5 more articles in the media than Hillstream BioPharma. MarketBeat recorded 5 mentions for Cara Therapeutics and 0 mentions for Hillstream BioPharma. Cara Therapeutics' average media sentiment score of 0.95 beat Hillstream BioPharma's score of 0.00 indicating that Cara Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Cara Therapeutics Positive
Hillstream BioPharma Neutral

Cara Therapeutics presently has a consensus target price of $3.93, suggesting a potential upside of 1,014.89%. Given Cara Therapeutics' higher possible upside, equities analysts plainly believe Cara Therapeutics is more favorable than Hillstream BioPharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cara Therapeutics
0 Sell rating(s)
6 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
Hillstream BioPharma
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

Cara Therapeutics has a beta of 0.69, indicating that its stock price is 31% less volatile than the S&P 500. Comparatively, Hillstream BioPharma has a beta of 3.08, indicating that its stock price is 208% more volatile than the S&P 500.

Cara Therapeutics received 666 more outperform votes than Hillstream BioPharma when rated by MarketBeat users. Likewise, 74.36% of users gave Cara Therapeutics an outperform vote while only 50.00% of users gave Hillstream BioPharma an outperform vote.

CompanyUnderperformOutperform
Cara TherapeuticsOutperform Votes
667
74.36%
Underperform Votes
230
25.64%
Hillstream BioPharmaOutperform Votes
1
50.00%
Underperform Votes
1
50.00%

Hillstream BioPharma has lower revenue, but higher earnings than Cara Therapeutics. Hillstream BioPharma is trading at a lower price-to-earnings ratio than Cara Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cara Therapeutics$20.97M0.92-$118.51M-$2.25-0.16
Hillstream BioPharmaN/AN/A-$8.47M-$0.72-5.33

44.7% of Cara Therapeutics shares are owned by institutional investors. Comparatively, 13.4% of Hillstream BioPharma shares are owned by institutional investors. 3.1% of Cara Therapeutics shares are owned by company insiders. Comparatively, 30.2% of Hillstream BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Cara Therapeutics beats Hillstream BioPharma on 10 of the 15 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CARA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CARA vs. The Competition

MetricCara TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$19.29M$7.31B$5.41B$8.72B
Dividend YieldN/A2.73%2.78%4.04%
P/E Ratio-0.1617.92119.1717.76
Price / Sales0.92320.752,182.7984.45
Price / CashN/A33.2136.4533.15
Price / Book0.345.844.954.46
Net Income-$118.51M$146.83M$111.51M$215.59M
7 Day Performance23.88%10.49%6.20%5.35%
1 Month Performance0.80%6.45%5.71%4.39%
1 Year Performance-87.66%0.03%6.50%1.77%

Cara Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
HILS
Hillstream BioPharma
0 of 5 stars
0.00 / 5 stars
$3.51
+2.0%
N/A+986.1%$61.79MN/A-4.881Gap Up
ELDN
Eledon Pharmaceuticals
3.0677 of 5 stars
3.07 / 5 stars
$2.45
-1.6%
$11.67
+376.2%
+78.9%$60.79MN/A-1.7820Short Interest ↑
News Coverage
Positive News
OVID
Ovid Therapeutics
4.9437 of 5 stars
4.94 / 5 stars
$0.86
+3.0%
$4.70
+449.6%
-72.0%$60.66M$390,000.00-1.1740Short Interest ↓
Gap Up
ANEB
Anebulo Pharmaceuticals
1.7624 of 5 stars
1.76 / 5 stars
$2.32
-4.9%
$6.67
+187.4%
+3.8%$60.16MN/A-6.272Short Interest ↑
RMTI
Rockwell Medical
3.6178 of 5 stars
3.62 / 5 stars
$1.97
+7.7%
$7.00
+255.3%
-48.2%$59.73M$83.61M-5.47237
VHAQ
Viveon Health Acquisition
0 of 5 stars
0.00 / 5 stars
$10.00
flat
N/AN/A$56.60MN/A0.00N/A
VACC
Vaccitech
0 of 5 stars
0.00 / 5 stars
$1.44
+0.7%
$7.63
+429.5%
-33.2%$55.51M$13.42M-1.0133Gap Up
BRNS
Barinthus Biotherapeutics
2.2067 of 5 stars
2.21 / 5 stars
$1.42
-1.7%
$5.50
+288.7%
N/A$55.23M$800,000.00-0.77130Positive News
Gap Up
CELU
Celularity
0 of 5 stars
0.00 / 5 stars
$2.83
-8.7%
N/A-42.3%$54.85M$17.98M0.00225Positive News
RLYB
Rallybio
3.0505 of 5 stars
3.05 / 5 stars
$1.32
+2.3%
$12.20
+824.2%
-76.6%$54.71MN/A-0.7030Short Interest ↓
News Coverage
Positive News

Related Companies and Tools

This page (NASDAQ:CARA) was last updated on 7/14/2024 by MarketBeat.com Staff

From Our Partners